论文部分内容阅读
目的:探讨依达拉奉联合血栓通治疗高血压脑出血的临床疗效。方法:将104例高血压脑出血患者按1:1随机分为联合组与对照组,其中联合组采用依达拉奉联合血栓通进行治疗,对照组采用复方丹参治疗,通过观察两组治疗前后神经功能缺损评分(NHSS)、Barthel指数(BI)和血肿变化情况,比较分析对照组与联合组疗效。结果:①联合组基本痊愈率为25.00%,总有效率分别为88.46%,均显著高于对照组(P<0.01或0.05),且未见明显不良反应。②治疗后21d,联合组患者NHSS评分下降和BI评分升高幅度均显著大于对照组(P<0.01或0.05),神经系统功能改善情况优于对照组。③治疗后,患者血肿容积明显减小(P<0.01或0.05),其中联合组血肿容积减少程度和吸收速度均显著大于对照组(P<0.05)。结论:依达拉奉联合血栓通治疗高血压性脑出血疗效显著,能促进神经功能恢复与血肿吸收,值得临床进一步推广。
Objective: To investigate the clinical efficacy of edaravone combined with Xueshuantong in treating hypertensive intracerebral hemorrhage. Methods: One hundred and four patients with hypertensive intracerebral hemorrhage were randomly divided into combined group and control group. The combined group was treated with edaravone and Xueshuantong. The control group was treated with compound Danshen, Neurological deficit score (NHSS), Barthel index (BI) and hematoma changes were compared between the control group and the combination group. Results: (1) The basic cure rate in combination group was 25.00%, the total effective rates were 88.46%, which were significantly higher than those in control group (P <0.01 or 0.05), and no obvious adverse reactions were found. ②At 21 days after treatment, the decrease of NHSS score and the increase of BI score in the combined group were significantly greater than those in the control group (P <0.01 or 0.05). The improvement of nervous system function was better than that of the control group. ③ After treatment, the hematoma volume of patients decreased significantly (P <0.01 or 0.05), and the reduction and absorption rate of hematoma volume in the combination group were significantly greater than those in the control group (P <0.05). Conclusion: Edaravone and Xueshuantong are effective in treating hypertensive intracerebral hemorrhage, which can promote neurological recovery and hematoma absorption and deserve further clinical promotion.